038 Stock Overview An oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
NovoCure Limited Competitors Price History & Performance
Summary of share price highs, lows and changes for NovoCure Historical stock prices Current Share Price US$28.85 52 Week High US$32.57 52 Week Low US$11.10 Beta 0.76 1 Month Change 78.25% 3 Month Change 94.34% 1 Year Change 141.32% 3 Year Change -60.71% 5 Year Change -63.48% Change since IPO 67.77%
Recent News & Updates
Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer Dec 03
Novocure FDA Approves Novocure’S Innovative HFE Transducer Arrays for Use with Optune Gio® for Glioblastoma Nov 21
Third quarter 2024 earnings released: US$0.28 loss per share (vs US$0.46 loss in 3Q 2023) Oct 31 NovoCure Limited Announces CFO Appointment
FDA Approves Novocure's Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer Oct 16
NovoCure Limited to Report Q3, 2024 Results on Oct 30, 2024 Oct 01 See more updates
Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer Dec 03
Novocure FDA Approves Novocure’S Innovative HFE Transducer Arrays for Use with Optune Gio® for Glioblastoma Nov 21
Third quarter 2024 earnings released: US$0.28 loss per share (vs US$0.46 loss in 3Q 2023) Oct 31 NovoCure Limited Announces CFO Appointment
FDA Approves Novocure's Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer Oct 16
NovoCure Limited to Report Q3, 2024 Results on Oct 30, 2024 Oct 01 Novocure Announces CEO Changes, Effective January 1, 2025
New major risk - Share price stability Jul 30
Second quarter 2024 earnings released: US$0.31 loss per share (vs US$0.54 loss in 2Q 2023) Jul 26
NovoCure Limited(NasdaqGS:NVCR) dropped from Russell 1000 Dynamic Index Jul 03 NovoCure Limited to Report Q2, 2024 Results on Jul 25, 2024 Jul 02
Novocure Announces the Presentation of Clinical Data from the Phase 3 Metis Trial Jun 05
Novocure Releases Topline Efficacy and Safety Data from the TIGER Study Investigating the Use of Tumor Treating Fields Therapy in the Treatment of Patients with Newly Diagnosed Glioblastoma in Germany May 24 NovoCure Limited announced that it expects to receive $400 million in funding May 03
First quarter 2024 earnings released: US$0.36 loss per share (vs US$0.50 loss in 1Q 2023) May 02
Now 24% overvalued Apr 29 NovoCure Limited Announces Results of the Metis Phase 3 Clinical Trial in Brain Metastases from Non-Small Cell Lung Cancer Apr 25
NovoCure Limited, Annual General Meeting, Jun 05, 2024 Apr 23
New minor risk - Shareholder dilution Apr 14
NovoCure Limited to Report Q1, 2024 Results on May 02, 2024 Apr 02
Now 20% overvalued after recent price rise Mar 05
Full year 2023 earnings released: US$1.95 loss per share (vs US$0.88 loss in FY 2022) Feb 28
Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer Jan 18
NovoCure Limited Announces Last Patient Enrolled in Phase 3 Trident Trial in Newly Diagnosed Glioblastoma Jan 09 NovoCure Limited Announces Executive Changes Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-Term Growth Drivers and an Accelerated Path to Profitability Nov 29
Third quarter 2023 earnings released: US$0.46 loss per share (vs US$0.25 loss in 3Q 2022) Oct 27
NovoCure Limited to Report Q3, 2023 Results on Oct 26, 2023 Oct 05
NovoCure Limited(NasdaqGS:NVCR) dropped from FTSE All-World Index (USD) Sep 18
Novocure Announces the Lancet Oncology Publishes Primary Data from Phase 3 Lunar Clinical Trial in Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies Aug 30
Levi & Korsinsky Notifies NovoCure Limited Investors of a Class Action Lawsuit and Upcoming Deadline Aug 05
New major risk - Revenue and earnings growth Jul 28
Second quarter 2023 earnings released: US$0.54 loss per share (vs US$0.23 loss in 2Q 2022) Jul 28 Novocure Announces Favorable Independent Data Monitoring Committee Recommendation to Continue Phase 3 Panova-3 Clinical Trial of Tumor Treating Fields Therapy in Pancreatic Cancer Jul 23
NovoCure Limited to Report Q2, 2023 Results on Jul 27, 2023 Jul 04
Holzer & Holzer, LLC Files Lawsuit Against NovoCure Limited Jun 21 Zai Lab and Novocure Announces Lunar Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies Jun 07
First quarter 2023 earnings released: US$0.50 loss per share (vs US$0.045 loss in 1Q 2022) May 05
Chief Operating Officer recently sold €155k worth of stock Mar 08
Full year 2022 earnings released: US$0.88 loss per share (vs US$0.56 loss in FY 2021) Feb 24
Novocure Announces Last Patient Enrolled in Pivotal PANOVA-3 Study of Tumor Treating Fields in Pancreatic Cancer Feb 16
Novocure Announces Executive Changes Jan 20 Zai Lab Limited and Novocure Announce Pivotal Lunar Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint
Insufficient new directors Nov 16
Third quarter 2022 earnings released: US$0.25 loss per share (vs US$0.13 loss in 3Q 2021) Oct 28
Novocure Announces 11 Presentations on Tumor Treating Fields in Multiple Solid Tumor Types at the American Society for Radiation Oncology 2022 Annual Meeting Oct 22
NovoCure Limited to Report Q3, 2022 Results on Oct 27, 2022 Oct 04
Chief Financial Officer recently sold €70k worth of stock Sep 08
Executive Chairman recently sold €57k worth of stock Aug 04
Second quarter 2022 earnings released: US$0.23 loss per share (vs US$0.14 loss in 2Q 2021) Jul 29
NovoCure Limited to Report Q2, 2022 Results on Jul 28, 2022 Jul 02
Novocure Enrolls First Patient in KEYNOTE-B36, a Pilot Study of Tumor Treating Fields Together with KEYTRUDA® for Patients with First-Line Stage III Non-Small Cell Lung Cancer Jun 22
Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer Jun 04
Chief Medical Officer recently sold €252k worth of stock May 14
First quarter 2022 earnings released: US$0.045 loss per share (vs US$0.04 loss in 1Q 2021) Apr 29
Insufficient new directors Apr 27 NovoCure Limited, Annual General Meeting, Jun 08, 2022
NovoCure Limited to Report Q1, 2022 Results on Apr 28, 2022 Apr 02
General Counsel recently sold €202k worth of stock Mar 08
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 25 Novocure Announces Resignation of Todd Longsworth as General Counsel
President recently bought €450k worth of stock Dec 01
NovoCure Limited Announces Last Patient Enrolled in Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-small Cell Lung Cancer Nov 24
Third quarter 2021 earnings released: US$0.13 loss per share (vs US$0.092 profit in 3Q 2020) Oct 29
FDA Grants Breakthrough Device Designation to the NovoTTF-200T™ System for Advanced Liver Cancer Sep 10
Key Executive recently sold €96k worth of stock Sep 09
Key Executive recently sold €713k worth of stock Aug 17
Executive Chairman recently sold €125k worth of stock Aug 05
Insufficient new directors Aug 02
Second quarter 2021 earnings released: US$0.14 loss per share (vs US$0.016 profit in 2Q 2020) Jul 30
Novocure Presents Final Safety and Efficacy Results from Its Phase 2 Pilot HEPANOVA Trial in Liver Cancer Jul 02
NovoCure Limited(NasdaqGS:NVCR) dropped from Russell 2500 Growth Index Jun 28
NovoCure Limited Initiates Usability Study for Flexible Torso Array Jun 17
Novocure Announces FDA Approval of IDE Supplement for Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer May 19
Chief Medical Officer recently sold €335k worth of stock May 14
First quarter 2021 earnings released: US$0.04 loss per share (vs US$0.04 profit in 1Q 2020) Apr 30
Chief Commercial Officer recently sold €304k worth of stock Mar 06 Shareholder Returns 038 DE Medical Equipment DE Market 7D -9.4% -3.3% -2.0% 1Y 141.3% -8.5% 6.9%
See full shareholder returns
Return vs Market: 038 exceeded the German Market which returned 6.9% over the past year.
Price Volatility Is 038's price volatile compared to industry and market? 038 volatility 038 Average Weekly Movement 20.3% Medical Equipment Industry Average Movement 6.7% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 038's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 038's weekly volatility has increased from 14% to 20% over the past year.
About the Company NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company’s TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer.
Show more NovoCure Limited Fundamentals Summary How do NovoCure's earnings and revenue compare to its market cap? 038 fundamental statistics Market cap €3.20b Earnings (TTM ) -€143.93m Revenue (TTM ) €555.15m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 038 income statement (TTM ) Revenue US$577.74m Cost of Revenue US$135.47m Gross Profit US$442.26m Other Expenses US$592.05m Earnings -US$149.78m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -1.38 Gross Margin 76.55% Net Profit Margin -25.93% Debt/Equity Ratio 181.4%
How did 038 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/23 00:38 End of Day Share Price 2024/12/23 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources NovoCure Limited is covered by 15 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Difei Yang Aegis Capital Corporation Gregory Gilbert Deutsche Bank Vijay Kumar Evercore ISI
Show 12 more analysts 
